Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02247479 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02247479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02247479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Terminated
Start date
September 18, 2014
Completion date
January 29, 2018
Enrollment
906 (actual)
Sites
145

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy